Literature DB >> 27583030

Emergency therapy for liver metastases from advanced VIPoma: surgery or transarterial chemoembolization?

Johann Dréanic1, Céline Lepère2, Mostafa El Hajjam3, Hervé Gouya4, Philippe Rougier2, Romain Coriat5.   

Abstract

VIPoma is a rare neuroendocrine tumor (NET) with a high potential to develop hepatic metastases and poor prognosis. The primitive tumor is nonsymptomatic and usually localized within the pancreas. Liver metastasis drives the prognosis and induces profuse watery diarrhea or renal failure. We herein present severe renal failure or diarrhea in two patients hospitalized in intensive care justifying emergency treatment of liver metastasis. The two patients experienced severe diarrhea due to a hypersecretion of vasoactive intestinal peptide (VIP) from liver metastasis released into the blood circulation. Therapeutic management was discussed and liver transarterial chemoembolization (TACE) was performed with chemotherapy-loaded embospheres, which cause necrosis of tumor lesions. TACE controlled the hormonal syndrome and made patients eligible for curative surgery. Tumor necrosis occurred and VIP levels collapsed. Surgery was performed in one of the two cases after TACE and the patient was considered in remission. Both patients were still alive after 3 years of follow up. Thus, TACE is feasible and appears to be an effective emergency treatment in patients with a VIP-hormonal syndrome due to liver metastases. Despite the biological disorder due to the hormonal secretion, an aggressive approach is warranted in VIP liver metastasis.

Entities:  

Keywords:  VIPoma; hepatectomy; neuroendocrine tumors (NET); systemic chemotherapy; transarterial chemo embolization (TACE); vasoactive intestinal peptide (VIP)

Year:  2016        PMID: 27583030      PMCID: PMC4981295          DOI: 10.1177/1758834016656495

Source DB:  PubMed          Journal:  Ther Adv Med Oncol        ISSN: 1758-8340            Impact factor:   8.168


  20 in total

1.  Isletcell tumour of the pancreas with peptic ulceration, diarrhoea, and hypokalaemia.

Authors:  W M PRIEST; M K ALEXANDER
Journal:  Lancet       Date:  1957-12-07       Impact factor: 79.321

2.  ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary.

Authors:  Marianne Pavel; Eric Baudin; Anne Couvelard; Eric Krenning; Kjell Öberg; Thomas Steinmüller; Martin Anlauf; Bertram Wiedenmann; Ramon Salazar
Journal:  Neuroendocrinology       Date:  2012-02-15       Impact factor: 4.914

3.  Elevated plasma and tissue levels of vasoactive intestinal polypeptide in the watery-diarrhea syndrome due to pancreatic, bronchogenic and other tumors.

Authors:  S I Said; G R Faloona
Journal:  N Engl J Med       Date:  1975-07-24       Impact factor: 91.245

Review 4.  Neuroendocrine pancreatic tumors: guidelines for management and update.

Authors:  William R Burns; Barish H Edil
Journal:  Curr Treat Options Oncol       Date:  2012-03

Review 5.  Pancreatic vipomas: spectrum of presentation and evolution of diagnostic and therapeutic modalities.

Authors:  S F Leavey; H Holloway; M G Courtney; B E Lane; D Royston; K D Buchanan; J F Fielding
Journal:  Ir J Med Sci       Date:  1995-01       Impact factor: 1.568

6.  Diagnosis and treatment of pancreatic vasoactive intestinal peptide endocrine tumors.

Authors:  Shaowei Song; Rui Shi; Baifeng Li; Yongfeng Liu
Journal:  Pancreas       Date:  2009-10       Impact factor: 3.327

7.  Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma.

Authors:  C G Moertel; M Lefkopoulo; S Lipsitz; R G Hahn; D Klaassen
Journal:  N Engl J Med       Date:  1992-02-20       Impact factor: 91.245

8.  Survival and prognostic factor analysis in patients with metastatic pancreatic endocrine carcinomas.

Authors:  Jonathan Strosberg; Nancy Gardner; Larry Kvols
Journal:  Pancreas       Date:  2009-04       Impact factor: 3.327

9.  Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease.

Authors:  A Frilling; J Li; E Malamutmann; K-W Schmid; A Bockisch; C E Broelsch
Journal:  Br J Surg       Date:  2009-02       Impact factor: 6.939

Review 10.  Clinical review 72: diagnosis and management of functioning islet cell tumors.

Authors:  R R Perry; A I Vinik
Journal:  J Clin Endocrinol Metab       Date:  1995-08       Impact factor: 5.958

View more
  1 in total

Review 1.  Treatment options of metastatic and nonmetastatic VIPoma: a review.

Authors:  Azadeh Azizian; Alexander König; Michael Ghadimi
Journal:  Langenbecks Arch Surg       Date:  2022-08-05       Impact factor: 2.895

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.